19.40
-0.81 (-4.01%)
| Penutupan Terdahulu | 20.21 |
| Buka | 20.07 |
| Jumlah Dagangan | 699,169 |
| Purata Dagangan (3B) | 931,185 |
| Modal Pasaran | 1,438,347,008 |
| Harga / Jualan (P/S) | 15.50 |
| Harga / Buku (P/B) | 2.91 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -163.17% |
| Margin Operasi (TTM) | -131.93% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 104.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 34.73% |
| Nisbah Semasa (MRQ) | 5.89 |
| Aliran Tunai Operasi (OCF TTM) | -161.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -84.53 M |
| Pulangan Atas Aset (ROA TTM) | -11.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Xencor, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.17 |
|
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.24% |
| % Dimiliki oleh Institusi | 111.90% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Primecap Management Co/Ca/ | 31 Mar 2026 | 10,338,022 |
| Bvf Inc/Il | 31 Mar 2026 | 7,133,720 |
| Ecor1 Capital, Llc | 31 Mar 2026 | 2,183,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |